Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS · Delayed Price · Currency is USD
23.83
-1.53 (-6.03%)
Oct 31, 2025, 4:00 PM EDT
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 500.76B JPY in the quarter ending September 30, 2025, with 12.14% growth. This brings the company's revenue in the last twelve months to 1.98T, up 12.56% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
1.98T JPY
Revenue Growth
+12.56%
P/S Ratio
3.30
Revenue / Employee
100.12M JPY
Employees
19,765
Market Cap
44.06B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.89T | 284.57B | 17.77% |
| Mar 31, 2024 | 1.60T | 323.21B | 25.28% |
| Mar 31, 2023 | 1.28T | 233.59B | 22.36% |
| Mar 31, 2022 | 1.04T | 82.38B | 8.56% |
| Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Jushi Holdings | 256.36M |
| Glass House Brands | 221.55M |
| Elite Pharmaceuticals | 105.45M |
| Silence Therapeutics | 27.17M |
| China New Energy Group Co. | 12.51M |
| Northwest Biotherapeutics | 1.09M |
Daiichi Sankyo Company News
- 2 days ago - Daiichi Sankyo (DSKYF) Reports Strong 1H Financial Results - GuruFocus
- 2 days ago - Daiichi Sankyo GAAP EPS of ¥70.52, revenue of ¥975.35B; updates FY outlook - Seeking Alpha
- 2 days ago - Daiichi Sankyo Company, Limited 2026 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 3 days ago - Daiichi Sankyo H1 Earnings Down, Cuts FY Earnings View, Lifts Revenue Forecast; Stock Down - Nasdaq
- 3 days ago - Daiichi Sankyo Co Ltd (TSE:4568) Q2 2026 Earnings Report Preview: What To Expect - GuruFocus
- 12 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions Transcript - Seeking Alpha
- 12 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses ESMO 2025 Highlights With Focus on Key Breast Cancer Trial Data and Regulatory Submissions - Slideshow - Seeking Alpha
- 20 days ago - Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials and Additional Data Across Industry-Leading ADC Portfolio at ESMO - Business Wire